ID   CEGT_RAT                Reviewed;         394 AA.
AC   Q9R0E0; O55149;
DT   07-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   29-MAY-2024, entry version 133.
DE   RecName: Full=Ceramide glucosyltransferase {ECO:0000305};
DE            EC=2.4.1.80 {ECO:0000269|PubMed:10393098};
DE   AltName: Full=GLCT-1;
DE   AltName: Full=Glucosylceramide synthase;
DE            Short=GCS;
DE   AltName: Full=Glycosylceramide synthase;
DE   AltName: Full=UDP-glucose ceramide glucosyltransferase;
DE   AltName: Full=UDP-glucose:N-acylsphingosine D-glucosyltransferase;
GN   Name=Ugcg {ECO:0000312|RGD:621870};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND
RP   MUTAGENESIS OF HIS-26; HIS-36; HIS-90; HIS-169; HIS-193; HIS-308; HIS-309;
RP   308-HIS-HIS-309 AND HIS-322.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=10393098; DOI=10.1042/bj3410395;
RA   Wu K., Marks D.L., Watanabe R., Paul P., Rajan N., Pagano R.E.;
RT   "Histidine-193 of rat glucosylceramide synthase resides in a UDP-
RT   glucose- and inhibitor (D-threo-1-phenyl-2-decanoylamino-3-
RT   morpholinopropan-1-ol)-binding region: a biochemical and mutational
RT   study.";
RL   Biochem. J. 341:395-400(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar; TISSUE=Liver;
RA   Buenning C., Orci L., Hirabayashi Y., Wieland F.T., Jeckel D.;
RT   "Purification and characterization of glucosylceramide synthase.";
RL   Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1532799; DOI=10.1083/jcb.117.2.259;
RA   Jeckel D., Karrenbauer A., Burger K.N., van Meer G., Wieland F.;
RT   "Glucosylceramide is synthesized at the cytosolic surface of various Golgi
RT   subfractions.";
RL   J. Cell Biol. 117:259-267(1992).
RN   [4]
RP   SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=9867864; DOI=10.1074/jbc.274.1.451;
RA   Marks D.L., Wu K., Paul P., Kamisaka Y., Watanabe R., Pagano R.E.;
RT   "Oligomerization and topology of the Golgi membrane protein
RT   glucosylceramide synthase.";
RL   J. Biol. Chem. 274:451-456(1999).
RN   [5]
RP   ACTIVE SITE, AND MUTAGENESIS OF ASP-92; LYS-124; ASP-144; GLY-224; GLY-225;
RP   GLU-235; ASP-236; GLY-247; ARG-272; ARG-275 AND TRP-276.
RX   PubMed=11337504; DOI=10.1074/jbc.m102612200;
RA   Marks D.L., Dominguez M., Wu K., Pagano R.E.;
RT   "Identification of active site residues in glucosylceramide synthase. A
RT   nucleotide-binding catalytic motif conserved with processive beta-
RT   glycosyltransferases.";
RL   J. Biol. Chem. 276:26492-26498(2001).
CC   -!- FUNCTION: Participates in the initial step of the glucosylceramide-
CC       based glycosphingolipid/GSL synthetic pathway at the cytosolic surface
CC       of the Golgi. Catalyzes the transfer of glucose from UDP-glucose to
CC       ceramide to produce glucosylceramide/GlcCer (such as beta-D-glucosyl-
CC       (1<->1')-N-acylsphing-4-enine) (PubMed:10393098, PubMed:1532799).
CC       Glucosylceramide is the core component of glycosphingolipids/GSLs,
CC       amphipathic molecules consisting of a ceramide lipid moiety embedded in
CC       the outer leaflet of the membrane, linked to one of hundreds of
CC       different externally oriented oligosaccharide structures (By
CC       similarity). Glycosphingolipids are essential components of membrane
CC       microdomains that mediate membrane trafficking and signal transduction
CC       (By similarity). They are implicated in many fundamental cellular
CC       processes, including growth, differentiation, migration, morphogenesis,
CC       cell-to-cell and cell-to-matrix interactions (By similarity). They are
CC       required for instance in the proper development and functioning of the
CC       nervous system. As an example of their role in signal transduction,
CC       they regulate the leptin receptor/LEPR in the leptin-mediated signaling
CC       pathway (By similarity). They also play an important role in the
CC       establishment of the skin barrier regulating keratinocyte
CC       differentiation and the proper assembly of the cornified envelope (By
CC       similarity). The biosynthesis of GSLs is also required for the proper
CC       intestinal endocytic uptake of nutritional lipids (By similarity).
CC       Catalyzes the synthesis of xylosylceramide/XylCer (such as beta-D-
CC       xylosyl-(1<->1')-N-acylsphing-4-enine) using UDP-Xyl as xylose donor
CC       (By similarity). {ECO:0000250|UniProtKB:O88693,
CC       ECO:0000250|UniProtKB:Q16739, ECO:0000269|PubMed:10393098,
CC       ECO:0000269|PubMed:1532799}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-acylsphing-4-enine + UDP-alpha-D-glucose = a beta-D-
CC         glucosyl-(1<->1')-N-acylsphing-4-enine + H(+) + UDP;
CC         Xref=Rhea:RHEA:12088, ChEBI:CHEBI:15378, ChEBI:CHEBI:22801,
CC         ChEBI:CHEBI:52639, ChEBI:CHEBI:58223, ChEBI:CHEBI:58885; EC=2.4.1.80;
CC         Evidence={ECO:0000269|PubMed:10393098};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12089;
CC         Evidence={ECO:0000305|PubMed:10393098};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-acylsphing-4-enine + UDP-alpha-D-xylose = a beta-D-
CC         xylosyl-(1<->1')-N-acylsphing-4-enine + H(+) + UDP;
CC         Xref=Rhea:RHEA:70243, ChEBI:CHEBI:15378, ChEBI:CHEBI:52639,
CC         ChEBI:CHEBI:57632, ChEBI:CHEBI:58223, ChEBI:CHEBI:189068;
CC         Evidence={ECO:0000250|UniProtKB:Q16739};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70244;
CC         Evidence={ECO:0000250|UniProtKB:Q16739};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N-(9Z-octadecenoyl)-sphing-4-enine + UDP-alpha-D-xylose =
CC         beta-D-xylosyl-(1<->1')-N-(9Z-octadecenoyl)-sphing-4-enine + H(+) +
CC         UDP; Xref=Rhea:RHEA:70247, ChEBI:CHEBI:15378, ChEBI:CHEBI:57632,
CC         ChEBI:CHEBI:58223, ChEBI:CHEBI:77996, ChEBI:CHEBI:189081;
CC         Evidence={ECO:0000250|UniProtKB:Q16739};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70248;
CC         Evidence={ECO:0000250|UniProtKB:Q16739};
CC   -!- PATHWAY: Lipid metabolism; sphingolipid metabolism.
CC       {ECO:0000305|PubMed:10393098}.
CC   -!- SUBUNIT: Interacts with RTN1; regulates the ceramide
CC       glucosyltransferase activity of UGCG. {ECO:0000250|UniProtKB:Q16739}.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane
CC       {ECO:0000269|PubMed:1532799, ECO:0000269|PubMed:9867864}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:9867864}.
CC   -!- DOMAIN: The D1, D2, D3, (Q/R)XXRW motif is a critical part of the GCS
CC       active site, involved in catalysis and UDP-sugar binding.
CC       {ECO:0000305|PubMed:11337504}.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 2 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF047707; AAD02464.1; -; mRNA.
DR   EMBL; AJ224156; CAA11853.1; -; mRNA.
DR   RefSeq; NP_113983.1; NM_031795.2.
DR   AlphaFoldDB; Q9R0E0; -.
DR   SMR; Q9R0E0; -.
DR   STRING; 10116.ENSRNOP00000021110; -.
DR   SwissLipids; SLP:000000912; -.
DR   CAZy; GT21; Glycosyltransferase Family 21.
DR   PhosphoSitePlus; Q9R0E0; -.
DR   PaxDb; 10116-ENSRNOP00000021110; -.
DR   Ensembl; ENSRNOT00000088872.2; ENSRNOP00000075148.1; ENSRNOG00000015644.6.
DR   Ensembl; ENSRNOT00055031586; ENSRNOP00055025519; ENSRNOG00055018570.
DR   Ensembl; ENSRNOT00060016626; ENSRNOP00060012988; ENSRNOG00060009852.
DR   Ensembl; ENSRNOT00065024899; ENSRNOP00065019475; ENSRNOG00065015043.
DR   GeneID; 83626; -.
DR   KEGG; rno:83626; -.
DR   UCSC; RGD:621870; rat.
DR   AGR; RGD:621870; -.
DR   CTD; 7357; -.
DR   RGD; 621870; Ugcg.
DR   eggNOG; KOG2547; Eukaryota.
DR   GeneTree; ENSGT00390000012898; -.
DR   InParanoid; Q9R0E0; -.
DR   OMA; HGSMPFH; -.
DR   OrthoDB; 2786173at2759; -.
DR   PhylomeDB; Q9R0E0; -.
DR   TreeFam; TF314564; -.
DR   BRENDA; 2.4.1.80; 5301.
DR   Reactome; R-RNO-9840309; Glycosphingolipid biosynthesis.
DR   UniPathway; UPA00222; -.
DR   PRO; PR:Q9R0E0; -.
DR   Proteomes; UP000002494; Chromosome 5.
DR   Bgee; ENSRNOG00000015644; Expressed in duodenum and 20 other cell types or tissues.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0008120; F:ceramide glucosyltransferase activity; IDA:RGD.
DR   GO; GO:0102769; F:dihydroceramide glucosyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0030154; P:cell differentiation; ISS:UniProtKB.
DR   GO; GO:1903575; P:cornified envelope assembly; ISS:UniProtKB.
DR   GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB.
DR   GO; GO:0006679; P:glucosylceramide biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0098856; P:intestinal lipid absorption; ISS:UniProtKB.
DR   GO; GO:0030216; P:keratinocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0033210; P:leptin-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0048666; P:neuron development; ISS:UniProtKB.
DR   GO; GO:0006497; P:protein lipidation; ISS:UniProtKB.
DR   GO; GO:0009966; P:regulation of signal transduction; ISS:UniProtKB.
DR   CDD; cd02520; Glucosylceramide_synthase; 1.
DR   InterPro; IPR025993; Ceramide_glucosylTrfase.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   PANTHER; PTHR12726; CERAMIDE GLUCOSYLTRANSFERASE; 1.
DR   PANTHER; PTHR12726:SF0; CERAMIDE GLUCOSYLTRANSFERASE; 1.
DR   Pfam; PF13506; Glyco_transf_21; 1.
DR   SUPFAM; SSF53448; Nucleotide-diphospho-sugar transferases; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Glycosyltransferase; Golgi apparatus; Lipid biosynthesis;
KW   Lipid metabolism; Membrane; Reference proteome; Sphingolipid metabolism;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN           1..394
FT                   /note="Ceramide glucosyltransferase"
FT                   /id="PRO_0000059178"
FT   TOPO_DOM        1..10
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305|PubMed:10393098"
FT   TRANSMEM        11..32
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        33..195
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:10393098"
FT   TRANSMEM        196..215
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        216..287
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305|PubMed:10393098"
FT   TRANSMEM        288..304
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        305..309
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:10393098"
FT   TRANSMEM        310..328
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        329..348
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305|PubMed:10393098"
FT   TRANSMEM        349..369
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        370..394
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305|PubMed:10393098"
FT   MOTIF           92
FT                   /note="D1"
FT                   /evidence="ECO:0000305"
FT   MOTIF           144
FT                   /note="D2"
FT                   /evidence="ECO:0000305"
FT   MOTIF           236
FT                   /note="D3"
FT                   /evidence="ECO:0000305"
FT   MOTIF           272..276
FT                   /note="(Q/R)XXRW"
FT                   /evidence="ECO:0000305"
FT   ACT_SITE        236
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305|PubMed:11337504"
FT   SITE            193
FT                   /note="May play an important role in binding to the
FT                   inhibitors DEPC and PDMP"
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MOD_RES         117
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O88693"
FT   VARIANT         8
FT                   /note="Q -> L (in strain: Wistar)"
FT   VARIANT         89
FT                   /note="D -> G (in strain: Wistar)"
FT   VARIANT         153
FT                   /note="T -> S (in strain: Wistar)"
FT   VARIANT         179
FT                   /note="G -> A (in strain: Wistar)"
FT   VARIANT         387
FT                   /note="T -> I (in strain: Wistar)"
FT   MUTAGEN         26
FT                   /note="H->A: Inhibits activity to less than 6%."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         26
FT                   /note="H->D: Inhibits activity to about 10%."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         26
FT                   /note="H->N: Inhibits activity to about 50%."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         26
FT                   /note="H->R: No effect on activity. Decreased sensitivity
FT                   to the inhibitor PDMP."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         36
FT                   /note="H->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         90
FT                   /note="H->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         92
FT                   /note="D->A: Inhibits activity to about 20%."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         124
FT                   /note="K->A: Completely abolishes catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         144
FT                   /note="D->A: Completely abolishes catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         169
FT                   /note="H->A: Inhibits activity to about 30%. Decreased
FT                   sensitivity to PDMP."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         193
FT                   /note="H->A: Inhibits activity to about 30%. Insensitive to
FT                   the inhibitors DEPC and PDMP."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         193
FT                   /note="H->D: Abolishes activity."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         193
FT                   /note="H->N: Inhibits activity to about 20%. Insensitive to
FT                   the inhibitors DEPC and PDMP."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         193
FT                   /note="H->R: Abolishes activity."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         224
FT                   /note="G->I: Completely abolishes catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         225
FT                   /note="G->I: Completely abolishes catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         235
FT                   /note="E->A: Inhibits activity to less than 1.5%."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         236
FT                   /note="D->A: Completely abolishes catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         247
FT                   /note="G->I: Leads to near complete loss of activity."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         272
FT                   /note="R->A: Completely abolishes catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         275
FT                   /note="R->A: Completely abolishes catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         276
FT                   /note="W->A: Completely abolishes catalytic activity."
FT                   /evidence="ECO:0000269|PubMed:11337504"
FT   MUTAGEN         308..309
FT                   /note="HH->AA: Inhibits activity to about 10%."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         308
FT                   /note="H->A: Inhibits activity to about 35%."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         309
FT                   /note="H->A: Inhibits activity to about 70%."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         322
FT                   /note="H->A: Inhibits activity to less than 6%."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         322
FT                   /note="H->D: Inhibits activity to less than 6%."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         322
FT                   /note="H->N: Inhibits activity to about 50%."
FT                   /evidence="ECO:0000269|PubMed:10393098"
FT   MUTAGEN         322
FT                   /note="H->R: Abolishes activity."
FT                   /evidence="ECO:0000269|PubMed:10393098"
SQ   SEQUENCE   394 AA;  44823 MW;  214581C0B8D9152C CRC64;
     MALLDLAQEG MALFGFVLFV VLWLMHFMSI IYTRLHLNKK ATDKQPYSKL PGVSLLKPLK
     GVDPNLINNL ETFFELDYPK YEVLLCVQDH DDPAIEVCKK LLGKYPNVDA RLFIGGKKVG
     INPKINNLMP AYEVAKYDLI WICDSGIRVI PDTLTDMVNQ MTERVGLVHG LPYVADRQGF
     AATLEQVYFG TSHPRSYISA NVTGFKCVTG MSCLMRKDVL DQAGGLIAFA QYIAEDYFMA
     KAIADRGWKF SMSTQVAMQN SGSYSISQFQ SRMIRWTKLR INMLPATIIC EPISECFVAS
     LIIGWAAHHV FRWDIMVFFM CHCLAWFIFD YIQLRGVQGG TLCFSKLDYA VAWFIRESMT
     IYIFLSALWD PTISWRAGRY RLRCGGTAEE ILDV
//
